Jun. 11 2026
Source Page: NHS Oversight Framework 2026/27Jun. 11 2026
Source Page: Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatmentJun. 11 2026
Source Page: Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatmentJun. 11 2026
Source Page: Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatmentJun. 11 2026
Source Page: Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatmentJun. 11 2026
Source Page: Friends and Family Test data – April 2026Jun. 11 2026
Source Page: Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatmentJun. 10 2026
Source Page: Emerging Technology Horizon Scan 2026Jun. 10 2026
Source Page: Emerging Technology Horizon Scan 2026 [pdf]Jun. 10 2026
Source Page: Advanced Foundation Trust Programme policies and guides